BYSI
BeyondSpring Inc. NASDAQ Listed Mar 9, 2017$0.87
+0.00%
vs $0.87
Mkt Cap $35.8M
52w Low $0.86
0.3% of range
52w High $2.44
50d MA $1.46
200d MA $1.64
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-0.0x
ROE
3.1%
P/FCF
-1.8x
RSI (14)
23.20
ATR (14)
$0.08
Beta
0.51
50d MA
$1.46
200d MA
$1.64
Avg Volume
37.6K
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
28 Liberty Street · Florham Park, NY 10005 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.54 | -0.05 | +90.3% | 1.68 | -1.8% | -4.2% | -0.6% | +1.2% | +1.2% | +4.3% | — |
| Nov 12, 2025 | AMC | — | -0.05 | — | 2.12 | -0.9% | -2.8% | +1.5% | -1.9% | -4.9% | +0.0% | — |
| Aug 13, 2025 | AMC | — | -0.04 | — | 2.00 | +0.0% | +0.5% | +0.5% | -8.4% | -5.4% | -1.7% | — |
| May 12, 2025 | AMC | — | -0.06 | — | 1.65 | +0.0% | +4.2% | -2.3% | +0.0% | -1.2% | +0.6% | — |
| Mar 27, 2025 | AMC | — | 0.08 | — | 1.50 | -4.7% | -4.0% | +0.0% | +12.5% | -3.1% | -4.5% | — |
| Aug 9, 2024 | AMC | — | -0.09 | — | 1.94 | -3.1% | -3.6% | +1.1% | -3.7% | -4.4% | +7.5% | — |
| Apr 29, 2024 | AMC | — | -0.11 | — | 2.22 | -0.9% | -9.5% | +2.5% | +4.9% | +4.2% | +1.3% | — |
| Apr 11, 2024 | AMC | — | -0.09 | — | 2.06 | -1.0% | +1.5% | -15.8% | +2.3% | +2.8% | -2.7% | — |
| Feb 28, 2024 | AMC | — | -0.16 | — | 1.29 | +0.8% | +3.1% | +12.8% | +9.3% | +76.8% | +17.9% | — |
| Sep 29, 2023 | AMC | — | -0.11 | — | 0.80 | -3.0% | +0.0% | -5.0% | -0.4% | +2.6% | -4.9% | — |
| Apr 18, 2023 | AMC | -0.58 | -0.19 | +67.4% | 1.36 | +1.5% | -20.6% | -0.9% | +0.9% | -10.2% | +3.1% | — |
| Mar 31, 2023 | AMC | — | -0.16 | — | 1.12 | +2.7% | +4.5% | -4.3% | -5.4% | +4.7% | +0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 2 | Baird | Maintains | Outperform → Outperform | — | $0.95 | $0.92 | -2.9% | -0.4% | -5.6% | +0.8% | +9.3% | -0.4% |
| Dec 2 | Jefferies | Downgrade | Buy → Hold | — | $4.93 | $4.74 | -3.9% | -9.9% | -9.5% | +2.2% | +13.6% | +3.6% |
| Dec 2 | BofA Securities | Downgrade | Buy → Underperform | — | $4.93 | $4.74 | -3.9% | -9.9% | -9.5% | +2.2% | +13.6% | +3.6% |
| Dec 1 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $12.77 | $5.86 | -54.1% | -61.4% | -9.9% | -9.5% | +2.2% | +13.6% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.91 | $18.30 | -20.1% | -33.0% | +3.0% | -4.2% | +1.3% | +0.5% |
| Sep 9 | Baird | Maintains | Outperform → Outperform | — | $23.01 | $23.87 | +3.7% | +5.7% | +0.5% | -4.1% | -3.7% | +1.8% |
| Aug 4 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $9.63 | $28.10 | +191.8% | +176.0% | -18.4% | +23.8% | +0.2% | -10.9% |
| Apr 5 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $10.80 | $10.70 | -0.9% | -1.6% | +0.6% | -3.9% | +3.4% | -3.1% |
| Jan 11 | BofA Securities | Maintains | Buy → Buy | — | $12.62 | $13.00 | +3.0% | +7.4% | -3.8% | -0.7% | +0.0% | -0.5% |
| Dec 29 | Evercore ISI | Maintains | Outperform → Outperform | — | $10.96 | $11.36 | +3.6% | +3.6% | +16.8% | -8.0% | -0.3% | -1.6% |
| Jun 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.61 | $17.92 | +7.9% | +7.2% | -3.7% | +0.2% | -3.4% | -18.4% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.51 | $12.45 | -0.5% | +2.1% | +0.3% | -4.9% | -6.6% | -1.5% |
| Feb 7 | Jefferies | Maintains | Buy → Buy | — | $17.20 | $17.89 | +4.0% | -0.8% | -1.2% | +0.2% | +4.0% | -3.7% |
| Jan 10 | Nomura Instinet | Maintains | Buy → Buy | — | $16.10 | $17.22 | +7.0% | +14.7% | -2.9% | -1.9% | +3.6% | -3.2% |
| Dec 3 | William Blair | Maintains | Outperform → Outperform | — | $12.53 | $13.00 | +3.8% | +1.0% | +9.4% | -1.2% | +1.9% | +6.3% |
| Jun 22 | Maxim Group | Maintains | Buy → Buy | — | $26.50 | $27.80 | +4.9% | +1.1% | +0.8% | +0.4% | -0.4% | -0.1% |
| Apr 4 | Rodman & Renshaw | Maintains | Buy → Buy | — | $19.76 | $19.85 | +0.5% | +0.8% | -0.6% | +0.4% | +1.2% | -0.6% |
No insider trades available.
8-K · 5.02
!!! Very High
BeyondSpring Inc. -- 8-K 5.02: Executive Change
Jun 4
8-K · 2.02
!! High
BeyondSpring Inc. -- 8-K 2.02: Earnings Results
May 13
8-K
Unknown — 8-K Filing
Plinabulin's Phase 3 survival benefit validates BeyondSpring's lead asset while $30M financing strengthens balance sheet, likely triggering near-term stock appreciation if commercialization timeline accelerates.
Mar 25
Institutional (13F) — Top 11
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Decheng Capital Llc | 3,800,702 | $6M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 607,934 | $997K | New | Mar 2026 |
| 3 | Northern Trust Corp | 69,268 | $114K | — | Mar 2026 |
| 4 | Tanaka Capital Management Inc | 26,296 | $43K | New | Mar 2026 |
| 5 | Renaissance Technologies Llc | 11,100 | $18K | Added | Mar 2026 |
| 6 | Jane Street Group, Llc | 11,124 | $18K | New | Dec 2025 |
| 7 | Morgan Stanley | 10,000 | $16K | Reduced | Dec 2025 |
| 8 | Ubs Group Ag | 1,170 | $2K | Reduced | Mar 2026 |
| 9 | Simplex Trading, Llc | 864 | $1K | New | Mar 2026 |
| 10 | Jpmorgan Chase & Co | 297 | $481 | Added | Mar 2026 |
| 11 | Bnp Paribas Financial Markets | 9 | $15 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Small Cap Core Fund | 5,429 | $9K | Mar 2026 |
| 2 | Guggenheim Active Allocation Fund | 133 | $180 | Feb 2026 |
Valuation
Market Cap
$35.8M
Enterprise Value
$22.6M
P/E (TTM)
—
Forward P/E
0.44x
PEG Ratio
0.29x
P/B
—
P/S
—
P/FCF
-1.75x
EV/EBITDA
—
Shares Out
40.4M
Financials (TTM)
Revenue
$0
Net Income
-$7.6M
EBITDA
-$8.0M
Free Cash Flow
-$20.1M
Op Cash Flow
-$20.0M
EPS Basic
$-0.20
EPS Diluted
$-0.19
EPS Forward
$1.98
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$25.9M
Total Liab.
$49.9M
Total Equity
-$24.0M
Cash
$12.6M
LT Debt
$0
Book Value/Sh
$-0.59
Debt/Equity
-0.01x
Current Ratio
1.54
Quick Ratio
1.54
Returns & Growth
ROE
3.1%
ROA
-3.9%
ROIC
-70.6%
Rev Growth YoY
+0.0%
EPS Growth YoY
+28.6%
Price Returns
2W
-22.3%
1M
-47.9%
3M
-41.6%
6M
-42.0%
12M
-56.5%
Technicals
52W High
$2.44
52W Low
$0.86
50d MA
$1.46
200d MA
$1.64
RSI (14)
23.20
ATR (14)
$0.08
Beta
0.51
Avg Volume
38K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 11:30pm
· Source: financialmodelingprep.com